Q2 EBIT in line; capex higher on Phase 2 preparations Continued strong biological performance for Batch #1 Operational metrics support further case de-risking ahead
Ticking off significant milestone; first smolt in pool The puzzle pieces are coming together in the short-term... …with important months ahead to show proof-of-concept
We expect limited est. changes to consensus Successful testing of all vital pool functions during Q4 On track for smolt release in Q2’22, we reiterate BUY
Limited est. changes apart from lower capex short-term De-risking of laminar water flow in Q4’21-Q1’22 On track for smolt release in Q2’22, we reiterate BUY
First pool filled with water, testing of water flow up next First smolt release in Q2’22 as previously indicated We expect limited estimate changes to consensus
Water inlet fixed and ready to test the water flow First smolt release in Q2’22 as previously indicated We expect limited estimate changes to consensus
Potential to scale up Kvalnes, pushing smolt release Longer to proof of concept, but lower biological risk De-risking of water technology shortly, we reiterate BUY
Plans to start excavation for the next pools in January Reduces risk of delays and interruption when ramping up We expect important milestones in H1’21, reiterate BUY
Skanska (BUY) Preview: Good outlook for EPS growth in ’21e Potential for lower capex and lower cost/kg if successful Initiating coverage with BUY and target price of NOK 62
Land-based salmon farmer with less complex technology Potential for lower capex and lower cost/kg if successful Initiating coverage with BUY and target price of NOK 62